Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Ionis Pharmaceuticals (IONS) PT Lowered to $68 at Laidlaw
October 18, 2021 7:53 AM EDTLaidlaw analyst Yale Jen lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $68.00 (from $78.00) while maintaining a Buy rating.
Tofersen in SOD1-ALS VALOR Trial Failed to Meet Primary Endpoint but Substantial Knowledge Learned... More